Linezolid therapy of Staphylococcus aureus experimental osteomyelitis

The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillln-susceptible Staphylococcus aureus (linezolid MIG, 2 mug/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial,,vith 25 mug of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 mug of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log(10) CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment.